WO2004105719A2 - Product for epidermal protection - Google Patents
Product for epidermal protection Download PDFInfo
- Publication number
- WO2004105719A2 WO2004105719A2 PCT/FR2004/001282 FR2004001282W WO2004105719A2 WO 2004105719 A2 WO2004105719 A2 WO 2004105719A2 FR 2004001282 W FR2004001282 W FR 2004001282W WO 2004105719 A2 WO2004105719 A2 WO 2004105719A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- fenugreek
- epidermis
- protective product
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a product for protecting the epidermis. It relates more particularly to a product allowing reinforced protection of the epidermis, which is based on the association of Nano Active Receptors (NAR) derived from Fenugreek
- the present invention provides a new product, intended to be used for nutraceutical and cosmetic applications, which allows enhanced protection of the epidermis.
- the active ingredient is isolated in a membrane composed of bioactive ingredients which provide the guiding role for the release of the active agents on a given target.
- the product uses the same molecular structure as Fenugreek to release its active ingredients.
- Fenugreek is made up of Nano-Receptive Receptacles that Engineers have isolated. Said product therefore makes it possible to release the active agents on a given target with great precision and increased efficiency, identical to the molecular structure of Fenugreek.
- the Fenugreek Isolated Receiver Nanos are incorporated into the lipid membrane, as illustrated in Figure 1, on which we find inside the microcapsule (1), the active (2) and the nano active receptors isolated from Fenugreek (3) in the membrane.
- the invention thus used protects the activity of the active ingredients and allows their release on the areas hitherto never reached by conventional active ingredients.
- the product is composed of hollow microspheres formed of lipid bilayers whose membrane is made up of phospholipids and bioactive ingredients: NARs (Nano Active Receptors) from Fenugreek.
- NARs Nano Active Receptors
- the characteristics of the liposomes of the invention can be modified.
- its composition and its size are modified.
- the affinity of the product is increased by modifying its composition, its electrical charge or by adding receptors or adhesion factors.
- the product of the invention protects the skin from the inside and from the outside (nutraceutical and cosmetic application).
- the vitamin and mineral intake decreases and leads to oxidation.
- the skin needs external and internal intakes of vitamins, fatty acids and antioxidants.
- the invention makes it possible to penetrate the different layers of the epidermis and to repair lesions with precision.
- Skin lesions are treated and the skin is rejuvenated from the inside and outside.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
PRODUIT DESTINE A LA PROTECTION DE L'EPIDERMEPRODUCT FOR THE PROTECTION OF THE SKIN
La présente invention concerne un produit de protection de l'épiderme. Il concerne plus particulièrement un produit permettant une protection renforcée de l'épiderme, qui est basé sur l'association de Nano Actifs Récepteurs (NAR) issus du FenugrecThe present invention relates to a product for protecting the epidermis. It relates more particularly to a product allowing reinforced protection of the epidermis, which is based on the association of Nano Active Receptors (NAR) derived from Fenugreek
Les populations sont de plus en plus à l'écoute de leur corps, et désirent de plus en plus retarder les effets du temps. Aussi les scientifiques sont sans cesse en quête de nouveaux produits. Mais les produits actuellement commercialisés, bien que très développés ne sont pas totalement satisfaisants.People are listening more and more to their bodies, and increasingly want to delay the effects of time. Also scientists are constantly looking for new products. However, the products currently on the market, although very developed, are not entirely satisfactory.
La présente invention propose un nouveau produit, destinée à être utilisée pour des applications nutraceutiques et cosmétiques, qui permet une protection renforcée de l'épiderme.The present invention provides a new product, intended to be used for nutraceutical and cosmetic applications, which allows enhanced protection of the epidermis.
Son principe, consiste à rendre le système de délivrance des actifs plus ciblé, efficace et intelligent, ce qui permet de protéger les actifs contre les agents extérieurs, d'améliorer leurs performances, d'augmenter leur durée de vie ou de conservation, et de différer leurs actions.Its principle consists in making the asset delivery system more targeted, efficient and intelligent, which makes it possible to protect assets against external agents, improve their performance, increase their lifespan or conservation, and defer their actions.
Les scientifiques connaissent les propriétés antidiabétiques de la plante appelée « Fenugrec » et, en tentant de découvrir le mécanisme de l'activité anti-diabétique de cette plante, le déposant s'est aperçu que la « Fenugrec » présentait un système exceptionnel de délivrance de molécules. Lors de ces recherches, il a été mis en évidence que cette plante avait la propriété de faciliter et de guider la circulation des molécules pour agir sur des points précis des couches de l'épiderme et des cellules. Selon l'invention, l'actif est isolé dans une membrane composée d'ingrédients bio-actifs qui assurent le rôle de guidage pour la libération des actifs sur une cible donnée.Scientists know the anti-diabetic properties of the plant called "Fenugreek" and, while trying to discover the mechanism of the anti-diabetic activity of this plant, the applicant has noticed that "Fenugreek" presented an exceptional system of delivery of molecules. During this research, it was revealed that this plant had the property of facilitating and guiding the circulation of molecules to act on specific points in the layers of the epidermis and cells. According to the invention, the active ingredient is isolated in a membrane composed of bioactive ingredients which provide the guiding role for the release of the active agents on a given target.
Selon une caractéristique complémentaire de l'invention, le produit utilise la même structure moléculaire que le Fenugrec pour libérer ses actifs. Le Fenugrec est constitué des Nano- Actifs Récepteurs que les Scientifiques ont isolés. Ledit produit permet donc de libérer les actifs sur une cible donnée avec une grande précision et une efficacité accrue, à l'identique de la structure moléculaire du Fenugrec.According to a complementary characteristic of the invention, the product uses the same molecular structure as Fenugreek to release its active ingredients. Fenugreek is made up of Nano-Receptive Receptacles that Scientists have isolated. Said product therefore makes it possible to release the active agents on a given target with great precision and increased efficiency, identical to the molecular structure of Fenugreek.
Les Nanos Actifs Récepteurs isolés du Fenugrec sont incorporés dans la membrane lipidique, tel que cela est illustré à la figure 1, sur laquelle on trouve à l'intérieur de la micro capsule (1), les actifs (2) et les nano actifs récepteurs isolés du Fenugrec (3) dans la membrane.The Fenugreek Isolated Receiver Nanos are incorporated into the lipid membrane, as illustrated in Figure 1, on which we find inside the microcapsule (1), the active (2) and the nano active receptors isolated from Fenugreek (3) in the membrane.
L'invention ainsi utilisée protège l'activité des ingrédients actifs et permet leur libération sur les zones jusqu'à maintenant jamais atteintes par des actifs classiques.The invention thus used protects the activity of the active ingredients and allows their release on the areas hitherto never reached by conventional active ingredients.
Il y a ainsi :There are thus:
- protection de phase active,- active phase protection,
- isolation d'actif,- asset isolation,
- libération contrôlée d'actif.- controlled release of assets.
Les avantages du produit selon l'invention sont :The advantages of the product according to the invention are:
- une libération prolongée,- prolonged release,
- une libération au bon moment, au bon endroit, - l'inoculation de petites quantités, donc pas de problème de toxicité,- release at the right time, in the right place, - inoculation of small quantities, so no toxicity problem,
- une durée de vie accrue,- an increased lifespan,
- une protection contre la lumière, l'oxygène, les réactions parasites,- protection against light, oxygen, parasitic reactions,
- une concentration élevée en principes actifs,- a high concentration of active ingredients,
- pas d'ingrédient d'origine animale, seulement des ingrédients d'origine végétale.- no ingredient of animal origin, only ingredients of vegetable origin.
Selon l'invention, le produit (liposome) est composé de micro- sphères creuses formées de bicouches de lipides dont la membrane est constituée par des phospholipides et des ingrédients bio-actifs : NARs (Nano Actif Récepteurs) issus du Fenugrec.According to the invention, the product (liposome) is composed of hollow microspheres formed of lipid bilayers whose membrane is made up of phospholipids and bioactive ingredients: NARs (Nano Active Receptors) from Fenugreek.
Selon les besoins, les caractéristiques des liposomes de l'invention peuvent être modifiées. Pour diminuer la vitesse de dégradation du produit et ralentir la libération de son contenu, on modifie sa composition et sa taille.As required, the characteristics of the liposomes of the invention can be modified. To reduce the rate of degradation of the product and slow the release of its content, its composition and its size are modified.
Pour augmenter la concentration de l'actif sur la cible, on augmente l'affinité du produit en modifiant sa composition, sa charge électrique ou en ajoutant des récepteurs ou des facteurs d'adhérence.To increase the concentration of the active ingredient on the target, the affinity of the product is increased by modifying its composition, its electrical charge or by adding receptors or adhesion factors.
Le produit de l'invention protège la peau de l'intérieur et de l'extérieur (application nutraceutiques et cosmétiques).The product of the invention protects the skin from the inside and from the outside (nutraceutical and cosmetic application).
Lorsque la peau vieillie, les apports en vitamines, minéraux diminuent et entraînent l'oxydation. La peau a besoin d'apports extérieurs et intérieurs en vitamines, acides gras et antioxydants. En effet, l'invention permet de pénétrer les différentes couches de l'épiderme et de réparer les lésions avec précision.When the skin ages, the vitamin and mineral intake decreases and leads to oxidation. The skin needs external and internal intakes of vitamins, fatty acids and antioxidants. In fact, the invention makes it possible to penetrate the different layers of the epidermis and to repair lesions with precision.
Lorsque le produit est ingéré oralement, ses nanoparticules circulent à travers les vaisseaux sanguins pour finir par pénétrer les différentes couches de l'épiderme.When the product is ingested orally, its nanoparticles circulate through the blood vessels to eventually penetrate the different layers of the epidermis.
Les lésions de la peau sont soignées et la peau est rajeunie de l'intérieur comme de l'extérieur.Skin lesions are treated and the skin is rejuvenated from the inside and outside.
Le produit selon l'invention trouve son application en :The product according to the invention finds its application in:
complément alimentaire anti-âge,anti-aging food supplement,
- complément alimentaire anti-oxydant beauté,- antioxidant beauty food supplement,
- sérum pour stimuler les cellules de la peau et leurs r égénérescences .- serum to stimulate skin cells and their regeneration.
Bien entendu, l'invention n'est pas limitée aux modes de réalisation décrits et représentés à titre d'exemples, mais elle comprend aussi tous les équivalents techniques ainsi que leurs combinaisons. Of course, the invention is not limited to the embodiments described and shown by way of examples, but it also includes all the technical equivalents and their combinations.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04742820A EP1648396A2 (en) | 2003-05-23 | 2004-05-22 | Product for epidermal protection |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR03/06552 | 2003-05-23 | ||
| FR0306552 | 2003-05-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004105719A2 true WO2004105719A2 (en) | 2004-12-09 |
| WO2004105719A3 WO2004105719A3 (en) | 2005-04-07 |
Family
ID=33484286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2004/001282 Ceased WO2004105719A2 (en) | 2003-05-23 | 2004-05-22 | Product for epidermal protection |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP1648396A2 (en) |
| WO (1) | WO2004105719A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3031669A1 (en) * | 2015-01-19 | 2016-07-22 | Ninapharm | ADVANCED DELIVERY SYSTEM |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196190A (en) * | 1990-10-03 | 1993-03-23 | Zenith Technology Corporation, Limited | Synthetic skin substitutes |
| US5847003A (en) * | 1996-06-04 | 1998-12-08 | Avon Products, Inc. | Oxa acids and related compounds for treating skin conditions |
| IL122776A (en) * | 1997-12-28 | 2004-07-25 | Dead Sea Lab Ltd | Gel composition for skin care and protection and a method for preparation thereof |
| WO2001024839A1 (en) * | 1999-10-01 | 2001-04-12 | Acrymed | Silver-containing compositions, devices and methods for making |
| FR2803513B1 (en) * | 2000-01-12 | 2003-12-19 | Oreal | USE OF DHEA AND / OR ITS PRECURSORS OR DERIVATIVES TO IMPROVE THE PAPYRACE OF THE SKIN |
| FR2827765B1 (en) * | 2001-07-27 | 2003-09-19 | Oreal | COMPOSITION BASED ON LIPID LAMELLAR VESICLES INCORPORATING AT LEAST ONE DHEA-BASED COMPOUND |
-
2004
- 2004-05-22 EP EP04742820A patent/EP1648396A2/en not_active Ceased
- 2004-05-22 WO PCT/FR2004/001282 patent/WO2004105719A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3031669A1 (en) * | 2015-01-19 | 2016-07-22 | Ninapharm | ADVANCED DELIVERY SYSTEM |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1648396A2 (en) | 2006-04-26 |
| WO2004105719A3 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1443898B1 (en) | Product containing a red alga extract of the genus porphyra and uses thereof for protecting cells | |
| AU2008337269B2 (en) | Formulations comprising exine shells | |
| São Pedro et al. | Chitosan: an option for development of essential oil delivery systems for oral cavity care? | |
| CA2616443C (en) | Uses of sporopollenin as an antioxidant | |
| Sarabandi et al. | Fractionation of flaxseed-derived bioactive peptides and their influence on nanoliposomal carriers | |
| EP2911680B1 (en) | Use of a flax extract, originating from the hydrolysis of flax proteins, as an active antimicrobial agent | |
| Fang et al. | Facile biofilm penetration of cationic liposomes loaded with DNase I/Proteinase K to eradicate Cutibacterium acnes for treating cutaneous and catheter infections | |
| TW200908891A (en) | Microencapsulating compositions, methods of making, methods of using and products thereof | |
| Paiva-Santos et al. | Nanotechnology-based formulations toward the improved topical delivery of anti-acne active ingredients | |
| WO2010004334A2 (en) | Exine shells | |
| EP1648396A2 (en) | Product for epidermal protection | |
| CH664490A5 (en) | PROCESS FOR THE PREPARATION OF COSMETIC COMPOSITIONS CONTAINING LYSED EXTRACTS FROM HAFNIA. | |
| FR2556218A1 (en) | Pharmaceutical product for local application consisting of the combination of a medicinal active ingredient and an enzymatic agent | |
| CA2522868C (en) | Vector comprising gastric protection for oral administration | |
| WO2010119192A1 (en) | Cosmetic and/or pharmaceutical composition comprising a relieving peptidic hydrolysate | |
| CA2426284A1 (en) | Anti-adiposis composition based on garlic bulb extracts | |
| EP1480610B1 (en) | Use of a hsp inducing compound to limit secondary effects of retinoids | |
| US20250326763A1 (en) | Melanin derived from palm pollen | |
| FR3015278A1 (en) | OILY MACERATE OF PATIRON (CUCURBITA MAXIMA) FOR A COSMETIC USE | |
| FR2832628A1 (en) | Product for inducing synthesis of stress protein, useful as food or cosmetic additive e.g. for protection against heat shock, contains extract of red algae | |
| Palshetkar et al. | Topical drug delivery for psoriasis using nanocarriers | |
| FR3018685B1 (en) | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF SALICARIA | |
| FR3049462A1 (en) | USE OF EXTRACTS OF DEINOCOCCUS BACTERIA AS COSMETIC OR PHARMACEUTICAL AGENTS | |
| CN116019778A (en) | Preparation method of peony pistil composite microcrystal capsule composition and application of peony pistil composite microcrystal capsule composition in resisting blue light, protecting cells, resisting allergy and resisting aging | |
| FR2835745A1 (en) | Retinoid containing cosmetic or dermatological composition used e.g. for combating skin aging, contains heat shock protein inducer, preferably Artemisia salina extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004742820 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004742820 Country of ref document: EP |